Caterina Marchioretti

Caterina Marchioretti

Auto-generated profile, based on publicly available information

Caterina Marchioretti


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in Science Advances
Verified
Journal Article
Closed access
DPDiana Piol
Diana Piol
LTLaura Tosatto
Laura Tosatto
EZEmanuela Zuccaro
Emanuela Zuccaro
EAEric N. Anderson
Eric N. Anderson
AFAntonella Falconieri
Antonella Falconieri
Maria PennutoMaria Pennuto
Maria Pennuto
Spinal and bulbar muscular atrophy is caused by polyglutamine (polyQ) expansions in androgen receptor (AR), generating gain-of-function toxicity that may involve phosphorylation. Using cellular and animal models, we investigated what kinases and phosphatases target polyQ-expanded AR, whether polyQ expansions modify AR phosphorylation, and how this contributes to neurodegeneration. Mass spectrometry showed that polyQ expansions preserve native phosphorylation and increase phosphorylation at conserved sites controlling AR stability and transactivation. In small-molecule screening, we identified that CDC25/CDK2 signaling could enhance AR phosphorylation, and the calcium-sensitive phosphatase calcineurin had opposite effects. Pharmacologic and genetic manipulation of these kinases and phosphatases modified polyQ-expanded AR function and toxicity in cells, flies, and mice. Ablation of CDK2 reduced AR phosphorylation in the brainstem and restored expression of Myc and other genes involved in DNA damage, senescence, and apoptosis, indicating that the cell cycle–regulated kinase plays more than a bystander role in SBMA-vulnerable postmitotic cells.

3 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
CMCaterina Marchioretti
Caterina Marchioretti
EZEmanuela Zuccaro
Emanuela Zuccaro
UPUdai Pandey
Udai Pandey
JRJessica D Rosati
Jessica D Rosati
MBManuela Basso
Manuela Basso
Maria PennutoMaria Pennuto
Maria Pennuto
Polyglutamine diseases are characterized by selective dysfunction and degeneration of specific types of neurons in the central nervous system. In addition, nonneuronal cells can also be affected as a consequence of primary degeneration or due to neuronal dysfunction. Skeletal muscle is a primary site of toxicity of polyglutamine-expanded androgen receptor, but it is also affected in other polyglutamine diseases, more likely due to neuronal dysfunction and death. Nonetheless, pathological processes occurring in skeletal muscle atrophy impact the entire body metabolism, thus actively contributing to the inexorable progression towards the late and final stages of disease. Skeletal muscle atrophy is well recapitulated in animal models of polyglutamine disease. In this review, we discuss the impact and relevance of skeletal muscle in patients affected by polyglutamine diseases and we review evidence obtained in animal models and patient-derived cells modeling skeletal muscle.

3 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
EZEmanuela Zuccaro
Emanuela Zuccaro
CMCaterina Marchioretti
Caterina Marchioretti
Marco PirazziniMarco Pirazzini
Marco Pirazzini
Maria PennutoMaria Pennuto
Maria Pennuto
Skeletal muscle is the most abundant tissue in the body and requires high levels of energy to function properly. Skeletal muscle allows voluntary movement and body posture, which require different types of fiber, innervation, energy, and metabolism. Here, we summarize the contribution received at the time of publication of this Introductory Issue for the Special Issue dedicated to “Skeletal Muscle Atrophy: Mechanisms at a Cellular Level”. The Special Issue is divided into three sections. The first is dedicated to skeletal muscle pathophysiology, the second to disease mechanisms, and the third to therapeutic development.

14 November 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
Daniele SabbatiniDaniele Sabbatini
Daniele Sabbatini
DGDomenico Gorgoglione
Domenico Gorgoglione
Giovanni MinerviniGiovanni Minervini
Giovanni Minervini
AFAurora Fusto
Aurora Fusto
MSMatteo Suman
Matteo Suman
EPElena Pegoraro
Elena Pegoraro
Ryanodine receptor 1-related myopathies (RYR1-RM) are caused by RYR1 gene variants and comprise a wide spectrum of histopathological manifestations. Here, we focus on patients carrying RYR1 variants and muscle histopathology consistent with central core disease (CCD) or multi-minicore disease (MmD). RNA-sequencing analyses of skeletal muscle biopsies obtained from both CCD and MmD patients and from healthy controls were performed to better understand the molecular pathways activated by RYR1 variants. Our analyses revealed that, beyond the well-established role of RYR1 in calcium homeostasis, broader cellular pathways are implicated. In CCD, differentially expressed genes were enriched for pathways related to oxidative stress response, SMAD signalling, and apoptosis, consistent with the role of intracellular calcium dysregulation in promoting mitochondrial dysfunction and cell death. In contrast, MmD patients exhibited enrichment of pathways related to immune activation. This was corroborated by the upregulation of GTPase-regulating genes and the down-regulation of transcriptional repressors such as ZFP36 and ATN1. When considering all RYR1-RM patients collectively, Wnt signalling, immune-related pathways, and oxidative phosphorylation emerged as shared enriched pathways, indicating possible convergent mechanisms across histopathological phenotypes. Our study suggests that complex gene regulation driven by RYR1 variants may be a unifying feature in CCD and MmD, offering new insight into potential therapeutic targets.